RBC Capital lowered the firm’s price target on Graphite Bio to $3 from $4 and keeps a Sector Perform rating on the shares. The analyst is updating the firm’s model to reflect the discontinuation of the sickle cell program as the company continues to seek strategic alternatives.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GRPH:
- Graphite Bio reports Q4 EPS (44c), consensus (49c)
- Graphite Bio downgraded to Neutral from Overweight at Cantor Fitzgerald
- Graphite Bio downgraded to Underperform from Neutral at BofA
- Cowen downgrades Graphite Bio on ‘uncertain strategy’ after update
- Graphite Bio downgraded to Market Perform from Outperform at Cowen